Can you provide an assessment and plan for a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Assessment and Plan for NSTEMI

All patients with NSTEMI require immediate risk stratification using validated scores (GRACE >140 or TIMI >4), dual antiplatelet therapy, anticoagulation, and timing of invasive strategy based on risk profile—with high-risk patients proceeding to angiography within 24 hours of admission. 1

Assessment

Initial Diagnostic Workup (Within 10 Minutes of Presentation)

• 12-lead ECG: Obtain immediately to confirm absence of ST-elevation and identify ST-depression, T-wave inversions, or dynamic changes 2, 3
• Serial troponins: Use high-sensitivity troponin with 0h/1h algorithm (preferred) or 0h/2h algorithm if validated. Results must be available within 60 minutes 1, 2, 3
  • If initial troponins inconclusive, repeat at 3 hours 3
  • Continue serial measurements for prognostic stratification 3

Risk Stratification (Mandatory)

Calculate objective risk scores immediately 1:

• GRACE score >140 = high risk
• TIMI score >4 = high risk

These scores dictate timing of invasive strategy and predict short/intermediate-term cardiovascular outcomes 1

Additional Baseline Labs

• Complete blood count (hemoglobin, hematocrit, platelets)
• Serum creatinine (adjust medication dosing)
• Blood glucose
• Lipid profile (obtain early during admission)
• INR if on anticoagulation 2

Monitoring Requirements

• Continuous cardiac rhythm monitoring until diagnosis confirmed or ruled out 3
• Admit to monitored unit (ICU/CCU for high-risk patients) 3
• Monitor for at least 24 hours or until PCI in low-risk patients 3
• >24 hours monitoring for patients at increased arrhythmia risk 3

Echocardiography

Perform immediately if:

• Hemodynamic instability
• Suspected mechanical complications
• Need to assess regional wall motion abnormalities (RWMAs are independent predictors of total occlusion) 2, 3

---

Plan

1. Immediate Antithrombotic Therapy

Antiplatelet Therapy (Start Immediately)

Aspirin 4, 3:

• Loading dose: 150-300 mg PO (or 75-250 mg IV)
• Maintenance: 75-100 mg daily indefinitely

P2Y12 Inhibitor (choose based on strategy) 4, 3:

For invasive strategy (preferred agents):

• Ticagrelor: 180 mg loading dose, then 90 mg BID (can give before knowing anatomy) 4, 3
• Prasugrel: 60 mg loading dose, then 10 mg daily (5 mg if age >75 years or weight <60 kg) — only after angiography, before PCI 3

For conservative strategy:

• Ticagrelor preferred over clopidogrel 3

Clopidogrel (300-600 mg load, 75 mg daily): Only if prasugrel/ticagrelor unavailable or contraindicated 3

Duration: Continue dual antiplatelet therapy for 12 months unless excessive bleeding risk (then consider 6 months) 4, 3

Anticoagulation (Start Immediately)

Choose one parenteral anticoagulant 4, 3:

• UFH: Continue for 48 hours
• Enoxaparin: Continue for duration of hospitalization (up to 8 days)
• Fondaparinux: Continue for duration of hospitalization (up to 8 days)

Do NOT routinely use GP IIb/IIIa inhibitors before knowing coronary anatomy 3

2. Invasive Strategy Timing (Based on Risk)

Very High Risk (Immediate Angiography <2 Hours)

Patients with 1:

• Refractory angina/ischemia
• Hemodynamic instability
• New or worsening heart failure
• Acute mitral regurgitation
• Sustained ventricular arrhythmias

High Risk (Early Invasive <24 Hours)

GRACE >140 or TIMI >4 1:

• Proceed to diagnostic angiography with intent to revascularize within 24 hours of admission
• This reduces recurrent ischemia, length of stay, and costs 1
• Use radial access to reduce bleeding complications 2

Intermediate Risk (Delayed Invasive 24-72 Hours)

Proceed to angiography within 24-72 hours 1

Low Risk (Conservative Strategy)

If conservative strategy selected and no recurrent symptoms 4:

• Perform stress test (preferably with imaging) or CCTA before discharge
• If stress test shows high risk → proceed to angiography
• If low risk → discharge with medical therapy

3. Adjunctive Medical Therapy

• Nitrates: Sublingual or IV for ongoing chest pain 2
• Beta-blockers: Unless contraindicated (heart failure, bradycardia, hypotension)
• High-intensity statin: Initiate immediately
• ACE inhibitor/ARB: Especially if LV dysfunction, hypertension, or diabetes

4. Pre-CABG Management (If Surgical Revascularization Planned)

Timing of P2Y12 inhibitor discontinuation 4:

• Clopidogrel: Stop 5 days before elective CABG
• Ticagrelor: Stop 7 days before elective CABG
• Prasugrel: Stop 7 days before elective CABG

Continue aspirin 4

Anticoagulation management 4:

• Continue UFH
• Stop enoxaparin 12-24 hours before CABG, bridge with UFH
• Stop fondaparinux 24 hours before CABG, bridge with UFH
• Stop bivalirudin 3 hours before CABG, bridge with UFH

5. Special Considerations

Common Pitfall: Do NOT delay angiography in high-risk patients due to advanced age, comorbidities, or multivessel disease—complete revascularization reduces mortality even in elderly/multimorbid patients 5

Contraindications to early invasive strategy 1:

• Extensive comorbidities making intervention futile
• Terminal illness
• Patient refusal
• Lack of catheterization laboratory access

---

Disposition

• High-risk patients: Cardiac ICU with continuous monitoring
• Intermediate/low-risk: Telemetry unit with rhythm monitoring
• Defibrillator patches: Place if ongoing ischemia until revascularization 2